BioGaia ABBGLAF 100 PS Ratio is 7.50 as of Jun. 28, 2026, which is 20% below its 10-year median of 9.41. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 953 Drug Manufacturers companies, BioGaia AB ranks worse than 83.95% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioGaia AB's share price is $12.20.
BioGaia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.63. Hence, BioGaia AB's PS Ratio for today is 7.50.
The historical rank and industry rank for BioGaia AB's PS Ratio or its related term are showing as below:
BGLAF'
s PS Ratio Range Over the Past 10 Years
Min: 6.64 Med: 9.41 Max: 14.4
Current: 7.78
During the past 13 years, BioGaia AB's highest PS Ratio was 14.40. The lowest was 6.64. And the median was 9.41.
BGLAF's PS Ratio is ranked worse than 83.95% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs BGLAF: 7.78
BioGaia AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of BioGaia AB was 8.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 15.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.00% per year.
During the past 13 years, BioGaia AB's highest 3-Year average Revenue per Share Growth Rate was 47.10% per year. The lowest was -9.30% per year. And the median was 15.30% per year.
Back to Basics: PS Ratio
BioGaia AB (OTCPK:BGLAF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BioGaia AB PS Ratio Related Terms
BioGaia AB PS Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BioGaia AB's Share Price of today is $12.20. BioGaia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BioGaia AB (BGLAF) has a PS Ratio of 7.50 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioGaia AB and its competitors. This is 20% below median its historical median of 9.41. Over the past decade, BioGaia AB's PS Ratio has ranged from 6.64 to 14.40. According to the industry distribution chart, BioGaia AB ranks #800 out of 953 companies in the Drug Manufacturers industry, placing it in the top 83.9%.
Is BioGaia AB's PS Ratio too high?
BioGaia AB's current PS Ratio of 7.50 is 20% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 6.64 to a high of 14.40. The Drug Manufacturers industry median PS Ratio is 2.20. BioGaia AB's value of 7.50 is 240.9% above this industry median. Based on the distribution chart, BioGaia AB ranks #800 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #800 out of 953 companies for PS Ratio. This places BioGaia AB in the lower half of its industry. The industry median PS Ratio is 2.20. BioGaia AB's value of 7.50 is 240.9% above this benchmark. Historically, BioGaia AB's own PS Ratio has ranged from 6.64 to 14.40 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 2.20, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current PS Ratio of 7.50 is 240.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current PS Ratio is 7.50, which is 20% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current PS Ratio of 7.50. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current PS Ratio is 7.50, which is 20% below median its 10-year median of 9.41 and 240.9% above the Drug Manufacturers industry median of 2.20. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current PS Ratio is 7.50 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
PS Ratio: 7.50 (20% below median its 10-year median of 9.41)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 240.9% above the Drug Manufacturers median (#800 of 953)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
